Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31081963 | 1.00 | MMP2 (0.40) | MMP2MEN1ALDH1A1CYP2C19KMT2A | |
| SCHEMBL26136436 | 1.00 | MMP2 (0.40) | MMP2MEN1ALDH1A1CYP2C19KMT2A | |
| SCHEMBL3240900 | 0.93 | MMP2 (0.40) | MMP2MEN1ALDH1A1CYP2C19KMT2A | |
| SCHEMBL31082046 | 0.93 | MMP2 (0.40) | MMP2MEN1ALDH1A1CYP2C19KMT2A | |
| SCHEMBL16618180 | 0.87 | MMP2 (0.36) | MMP2MEN1ALDH1A1CYP2C19KMT2A | |
| SCHEMBL16618179 | 0.87 | MMP2 (0.36) | MMP2MEN1ALDH1A1CYP2C19KMT2A | |
| SCHEMBL16820690 | 0.83 | MMP2 (0.40) | MMP2MEN1ALDH1A1CYP2C19KMT2A | |
| SCHEMBL16617927 | 0.83 | MMP2 (0.37) | MMP2MEN1ALDH1A1CYP2C19KMT2A | |
| SCHEMBL18010285 | 0.83 | MMP2 (0.37) | MMP2MEN1ALDH1A1CYP2C19KMT2A | |
| SCHEMBL1651723 | 0.80 | CHRNB2 (0.40) | MMP2MEN1ALDH1A1CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745462-B2 | Quinoline-2-one derivatives for the treatment of airways diseases | NOVARTIS AG (CH) | 2010-06-29 | — | — | US | disclosed |
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | NOVARTIS AG (CH) | 2007-03-22 | — | — | US | disclosed |
| EP-1613315-A1 | QUINOLINE-2-ONE-DERIVATIVES FOR THE TREATMENT OF AIRWAYS DISEASES | Novartis AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087142-A1 | QUINOLINE-2-ONE-DERIVATIVES FOR THE TREATMENT OF AIRWAYS DISEASES | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | ADRB2, ADRA2C, ADRB1 | MMP2 4054/4885MEN1 2971/4885ALDH1A1 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.